(Press-News.org) Contact information: Jessica Maki
jmaki3@partners.org
617-525-6373
Brigham and Women's Hospital
Most high-risk cardiac devices in use today approved as modifications to previously-approved devices
Device 'supplement' applications are generally not accompanied by new clinical testing, with implications for patient safety
Boston – The Food and Drug Administration (FDA) ensures that high-risk medical devices, such as implantable cardioverter-defibrillators and pacemakers, are safe and effective through its premarket approval (PMA) pathway, during which manufacturers must collect preclinical and clinical data before the device is approved. However, a new study from researchers at Brigham and Women's Hospital (BWH) shows that most cardiac implantable electronic devices (CIEDs) used by physicians today were approved as changes, or "supplements," to existing PMA-approved models, often without the collection of new clinical data. These findings are published in JAMA: The Journal of the American Medical Association on January 21, 2014.
"The original PMA process is widely considered to be the most rigorous regulatory review pathway for device approval in the world," explained Aaron Kesselheim, MD, JD, MPH, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH, and senior investigator of this study. "However, we found that many CIED models currently used by clinicians in the United States were approved via the PMA supplement process, not as original PMAs. Key cardiac devices recalled in recent years—such as the St. Jude Medical Riata and Medtronic Sprint Fidelis defibrillator leads—were approved through the PMA supplement process."
Supplements to existing high-risk cardiac devices may include major or minor design changes, as well as routine changes in labeling, materials or packaging. The researchers used the FDA's PMA database to review CIEDs approved from 1979 through 2012. For each supplement, they collected the date approved, type of supplement, and the nature of the changes. They then calculated the number of supplements approved per PMA and analyzed trends in the different supplement regulatory categories over time. For supplements indicating major design changes from 2010-2012, they identified how often additional clinical data were collected.
They found that since the first CIED was approved via PMA in 1979, the FDA has authorized 5829 supplements for 77 PMA applications, translating to an average of 50 supplements per PMA. Over a third of supplements involved a change to a device's design or materials, and in the majority of these cases the FDA deemed that new clinical data were not necessary for approval. PMA applications remained active via successive supplements over a median period of 15 years, with 79% of the 77 PMAs approved during the study still being the subject of at least 1 supplement in 2012.
"We found that most new cardiac implantable electronic device models currently in use were deemed deemed safe and effective without requiring new clinical data," said Benjamin Rome, a Harvard Medical School student and lead author of the study. Small changes made in each successive supplement add up over time and can lead to a device that looks nothing like the original product on which the supplement's approval was based. These small changes may also have important implications for patient safety, as evidenced by the Riata and Sprint Fidelis recalls.
"The PMA supplement process allows manufactures to easily update devices, which means that useful technological advances can be rapidly integrated in clinical care," explains Daniel Kramer, MD, a cardiac electrophysiologist at the Beth Israel Deaconess Medical Center and co-author on the study. "However, a large number of the cardiac devices implanted in patients are approved as PMA supplements, and clinicians and patients should consider the strengths and limitations of the PMA supplement approval process when making decisions about the use of these high-risk devices."
The researchers note that approval of high-risk devices as PMA supplements reinforces the need to perform rigorous post-market surveillance. They hope that their results will encourage the clinical community to conduct more comparative effectiveness studies to guide clinicians who need to choose among many similar device models.
###
Mr. Rome was supported by a Harvard Medical School fellowship. Dr. Kramer is the Lois Green Scholar at the Hebrew SeniorLife Institute for Aging Research and is supported by a career development award from the Harvard Catalyst Clinical and Translational Research Center and a Paul B. Beeson career development award in aging (1K23AGO45963). Dr. Kesselheim is supported by a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, a Greenwall Faculty Scholarship in Bioethics, and a career development award from the Agency for Healthcare Research and Quality (K08HS18465-01).
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.
Most high-risk cardiac devices in use today approved as modifications to previously-approved devices
Device 'supplement' applications are generally not accompanied by new clinical testing, with implications for patient safety
2014-01-22
ELSE PRESS RELEASES FROM THIS DATE:
New sequencing tools give up close look at yeast evolution
2014-01-22
New sequencing tools give up close look at yeast evolution
Highlights in this week's Molecular Biology and Evolution
The baker's yeast Saccharomyces cerevisiae has been associated with human activities for thousands of ...
All FDA drug approvals not created equal
2014-01-22
All FDA drug approvals not created equal
Many patients and physicians assume that the safety and effectiveness of newly approved drugs is well understood by the federal Food and Drug Administration (FDA) —but a new study by researchers at Yale School of Medicine shows ...
Hedges and edges help pigeons learn their way around
2014-01-22
Hedges and edges help pigeons learn their way around
A study has found that homing pigeons' ability to remember routes depends on the complexity of the landscape below, with hedges and boundaries between urban and rural areas ...
Large amounts of folic acid shown to promote growth of breast cancer in rats
2014-01-22
Large amounts of folic acid shown to promote growth of breast cancer in rats
Role of folate in development, progression of breast cancer highly controversial
TORONTO, Jan. 21, 2014---Folic acid supplements at levels consumed by breast cancer patients and survivors ...
Cochrane Review of dihydroartemisinin-piperaquine
2014-01-22
Cochrane Review of dihydroartemisinin-piperaquine
Cochrane review of dihydroartemisinin-piperaquine for treating uncomplicated malaria
'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' ...
Researchers identify innate channel that protects against pain
2014-01-22
Researchers identify innate channel that protects against pain
Scientists have identified a channel present in many pain detecting sensory neurons that acts as a 'brake', limiting spontaneous pain. It is hoped that the new research, published today ...
Study: Electric drive vehicles have little impact on US pollutant emissions
2014-01-22
Study: Electric drive vehicles have little impact on US pollutant emissions
A new study from North Carolina State University indicates that even a sharp increase in the use of electric drive passenger vehicles (EDVs) by 2050 would not significantly reduce ...
Study: 'Icy' technique improves robotic kidney transplants
2014-01-22
Study: 'Icy' technique improves robotic kidney transplants
DETROIT – A collaboration of surgeons at Henry Ford Hospital and Medanta Hospital in India successfully transplanted kidneys into 50 recipients using an innovative robot-assisted procedure in which ...
More diseases from air pollution uncovered by improved data material
2014-01-22
More diseases from air pollution uncovered by improved data material
At rest, we breathe approx. 12-15 times per minute, and for each inhalation we change approx. one litre of air. Depending on the activity level, this makes up a daily quantity in the order of twenty cubic metres ...
Understanding the functioning of a new type of solar cell
2014-01-21
Understanding the functioning of a new type of solar cell
Photovoltaic energy conversion offers one of the best means for the future of renewable energy in the world. The efficiency of solar cells depends heavily upon the light-absorbing materials ...
LAST 30 PRESS RELEASES:
Milken Institute, Ann Theodore Foundation announce more than $2.5 million in new funding for sarcoidosis research and launch new call for proposals
Boston University professor to receive 2025 Eugene Braunwald Academic Mentorship Award
Pusan National University researchers reveal how forest soil properties influence arsenic mobility and toxicity in soil organisms
Korea University researchers find sweet taste cells resist nerve damage through c-Kit protein
HealthFORCE, AAPA, and West Health release “Aging Well with AI” – first in a two part series on AI and the healthcare workforce
The real reasons Endurance sank — study finds Shackleton knew of ship’s shortcomings
Marine heatwaves have hidden impacts on ocean food webs and carbon cycling
Order from disordered proteins
Rocket test proves bacteria survive space launch and re-entry unharmed
New wheat diversity discovery could provide an urgently-needed solution to global food security
Could reducing inflammation help combat fatigue in people with early-stage breast cancer?
Traumatic brain injuries in older adults linked to increased risk of dementia
New intervention helps pediatricians promote early peanut introduction to prevent peanut allergy
New survey: Most Americans believe plasma donation saves lives, yet few have donated
New tools boost pediatricians’ adherence to peanut allergy guidelines 15-fold
Research unearths origins of Ancient Egypt’s Karnak Temple
Reevaluating nonoperative management for pediatric uncomplicated acute appendicitis
Metabolically active visceral fat linked to aggressive endometrial cancer, new study reveals
Scientists glimpse how enzymes “dance” while they work, and why that’s important
California partnership aided COVID-19 response and health equity, report finds
University of Oklahoma secures $19.9 million for revolutionary radar technology
Study finds restoring order to dividing cancer cells may prevent metastasis
High-accuracy tumor detection with label-free microscopy and neural networks
Wayne State research reveals fetuses exposed to Zika virus have long-term immune challenges
Researchers deconstruct chikungunya outbreaks to improve prediction and vaccine development
Study finds one-year change on CT scans linked to future outcomes in fibrotic lung disease
Discovery of a novel intracellular trafficking pathway in plant cells
New tool helps forecast volcano slope collapses and tsunamis
Molecular coating cleans up noisy quantum light
From Parkinson's to rare diseases, discovered a key switch for cellular health
[Press-News.org] Most high-risk cardiac devices in use today approved as modifications to previously-approved devicesDevice 'supplement' applications are generally not accompanied by new clinical testing, with implications for patient safety